Teenager who received Elevidys, Sarepta’s Duchenne gene therapy, dies
Elevidys was approved after intense debate at the FDA, as officials and reviewers disagreed over how strong the evidence was ...
Is This Stock a Buy After a Massive 20% Drop in 1 Day?
Things are going from bad to worse for Sarepta Therapeutics (NASDAQ: SRPT), a biotech focusing on gene therapies. The company ...
GEN - Genetic Engineering and Biotechnology News8h
StockWatch: After DMD Patient Death, Analysts Still Bullish on Sarepta
Why didn’t analysts share the same fear that gripped investors about Sarepta stock? One reason is the known risk of acute liver injury associated with adeno-associated virus vector (AAV)-based gene ...
Analysts remain optimistic about Elevidys after Sarepta reports patient death
Shares of Sarepta Therapeutics (SRPT) are under pressure on Tuesday after the company shared a safety update related to its Elevidys, the only ...
BioSpace3d
In Wake of Elevidys Death, Duchenne Patient Community Vows to Push On
After Sarepta reported the death of a patient who had recently taken the gene therapy Elevidys, patient advocacy group Parent ...
BioPharma Dive5d
Duchenne patient dies after receiving Sarepta gene therapy
A young man treated with Elevidys died of acute liver failure. The case may give doctors pause before prescribing the ...
Sarepta: Should Investors Run For The Exit?
Sarepta stock may recover sharply as additional information and data reveal that the adverse event reported by the company is ...
pharmaphorum4d
Sarepta slumps on Elevidys patient death
The tragic death of the 16-year-old boy came as a result of acute liver failure, which is a known side effect of Elevidys and ...
Sarepta plunges after death linked to Elevidys (update)
Sarepta Therapeutics (SRPT) stock drops 25% as the company reports a patient death linked to Elevidys, its gene therapy developed with Roche (RHHBY). Read more here.
GEN - Genetic Engineering and Biotechnology News5d
DMD Patient Dies After Treatment with Sarepta Gene Therapy
The patient, whom Sarepta described as a young man and later told news outlets was 16 years old, suffered acute liver failure ...
BioSpace4d
Sarepta’s Elevidys Death, FDA’s Vaccine Move, Weldon Whiplash, PDUFAs in Cardio
Sarepta will update Elevidys’ label after a patient died following treatment; the FDA issues flu vaccine recommendations ...
Sarepta Therapeutics Reports Patient Death Post Elevidys Gene Therapy Treatment, Stock Plunges
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stock is sliding. The company shared an update on Elevidys (delandistrogene moxeparvovec-rokl), the only approved gene therapy in patients with Duchenne ...